Today, Takeda announced positive topline results from 2 pivotal phase 3 trials of zasocitinib (TAK-279; Takeda), demonstrating superiority over placebo across key efficacy end points in adults with ...
Placebo have told their critics to "get a life" after they were struck with "many insults" following a recent festival performance. The 'Every You Every Me' hitmakers took to Instagram to hit back at ...
With Halloween around the corner, the bogeyman of biotech—high placebo rate—has spooked investors in Immunic, sending its stock down 71% to $2.60 in premarket trading. The company blamed the response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback